InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (2 ops.)
Insider track record
OtherDisclosed buys
3
Disclosed sells
2
T+90 hit rate
50%
T+90 mean return
-19.5%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by New Enterprise Associates 16, L.P.. Director active across 6 companies, notably Trevi Therapeutics, Inc.. Aggregated, 7 filings have been recorded. Split: 3 buys · 2 sells. Total volume traded: €6.3m. Activity tracked since 10 December 2021. The latest transaction was filed on 23 December 2024 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations7 total
554,250 shares@ US$3.20100.0% of flowCommon StockSEC:0000950170-24-139630:0
Canonical exit: 23 Mar 2025 (T+90)
2,000,000 shares0Common StockSEC:0001209191-23-037333:0
4,294,207 sharesCommon StockSEC:0001209191-22-059440:0
5,931,843 shares@ €0.0609100.0% of flowCommon StockSEC:0001209191-22-032327:0
2,631,578 shares@ US$1.900.23% mcap100.0% of flowCommon StockSEC:0001209191-22-024301:0
Canonical exit: 10 Jul 2022 (T+90)
37,570 shares@ US$1.32150.0% of flowCommon StockSEC:0001209191-21-071265:0
1,851,852 sharesCommon StockSEC:0001209191-21-061090:0
Canonical exit: 16 Jan 2022 (T+90)
7 of 7 declarations
About New Enterprise Associates 16, L.P.
New Enterprise Associates 16, L.P. is a director and insider at Trevi Therapeutics, Inc., Metacrine, Inc., and Genocea Biosciences, INC.
